trending Market Intelligence /marketintelligence/en/news-insights/trending/wv4f96198mqsh-2he3htjq2 content esgSubNav
In This List

Acorda Therapeutics grants Scopia Capital 2 board seats

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Acorda Therapeutics grants Scopia Capital 2 board seats

Acorda Therapeutics Inc. entered into a cooperation agreement with Scopia Capital Management LP, a minority investor in the company.

Under the terms of the agreement, Scopia will be entitled to appoint two directors to Acorda's board in the period between the 2018 annual meeting and Jan. 1, 2019. Scopia will also support the U.S.-based biotechnology company's nominees for the board at the 2018 annual meeting.

In August 2017, Scopia called on Acorda's board to review all strategic alternatives, including a sale of the company.

Scopia held about 18.13% of Acorda's outstanding common shares as of Dec. 31, 2017, according to S&P Global Market Intelligence data.